A genome-wide screen of HLA class I–low tumor cells also revealed that polycomb repressor complex 2 (PRC2) can silence HLA expression, and that in vitro PRC2 inhibition with drugs such as EZH2 inhibitors can enhance HLA expression (Burr et al. 2019). Here, EZH2 is linked to neoplasm.